HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY

被引：0

作者：

D'agostino, M. A. ^{[1
]}

Conaghan, P. G. ^{[2
]}

Gaillez, C. ^{[3
]}

Naredo, E. ^{[4
]}

Mandl, P. ^{[5
]}

Carron, P. ^{[6
]}

Senolt, L. ^{[7
,8
]}

Rosa, J. ^{[9
]}

Lopez-Rodriguez, A. ^{[10
]}

Goyanka, P. ^{[11
]}

Sahoo, B. G. ^{[12
]}

Bao, W. ^{[13
]}

Schett, G. ^{[14
]}

Boers, M. ^{[15
]}

机构：

[1] Univ Cattolica Sacro Cuore, Rheumatol, Rome, Italy

[2] Univ Leeds, Rheumatol, London, England

[3] Novartis Pharma AG, Immunol & Rheumatol, Basel, Switzerland

[4] Hosp Fdn Jimenez Diaz & Autonoma Univ, Dept Rheumatol & Joint & Bone Res Unit, Madrid, Spain

[5] Med Univ Vienna, Div Rheumatol, Vienna, Austria

[6] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium

[7] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic

[8] Charles Univ Prague, Dept Rheumatol, Prague, Czech Republic

[9] Hosp Italiano Buenos Aires & Univ Inst, Rheumatol Unit, Internal Med Serv, Buenos Aires, DF, Argentina

[10] PSOAPS Psoriasis Clin & Res Ctr, Dermatol Country, Guadalajara, Mexico

[11] Novartis Healthcare Pvt Ltd, Clin Project Management, Hyderabad, India

[12] Novartis Healthcare Pvt Ltd, Biostat, Hyderabad, India

[13] Novartis Pharmaceut, Biostat, East Hanover, NH USA

[14] FAU Erlangen Nurnberg & Univ Klinikum Erlangen, Dept Internal Med 3, Erlangen, Germany

[15] Vrije Univ, Amsterdam UMC, Dept Epidemiol & Data Sci, Amsterdam, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Psoriatic arthritis; bDMARD;

D O I：

10.1136/annrheumdis-2023-eular.2548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0225

引用

页码：340 / 341

页数：2

共 50 条

[41] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
Gratacos-Masmitja, J.
Turkiewicz, A.
Dokoupilova, E.
Gellett, A. M.
Sprabery, T.
Geneus, V. J.
Constantin, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1154 - 1154
[42] Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
Ogdie, Alexis
Reddy, Soumya M.
Gillespie, Sarah H.
Husni, M. Elaine
Scher, Jose U.
Salomon-Escoto, Karen
Kay, Jonathan
Luedders, Brent A.
Curtis, Jeffrey R.
Shields, Alisa J. Stephens
Chakravarty, Soumya D.
Gong, Cinty
Walsh, Jessica A.
TRIALS, 2025, 26 (01)
[43] ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA) AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDS: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPSAKE 1 AND 2 TRIALS
Ogdie, A.
Coates, L.
De Toledo, R. Acayaba
Biljan, A.
Jones, H.
Tacelosky, K.
Yue, C.
Padilla, B.
Bergman, M.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1582 - 1582
[44] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Rahman, Proton
Orbai, Ana-Marie
Gellett, Amanda
Kerr, Lisa
Constantin, Arnaud
Gladman, Dafna
JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 847 - 848
[45] A PHASE 2B/3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB, A SELECTIVE JAK1 INHIBITOR, IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
Tanaka, Y.
Takeuchi, T.
Yamaoka, K.
Oribe, M.
Kawano, M.
Zhou, Y.
Othman, A. A.
Pangan, A. L.
Kitamura, S.
Matsuda, N.
Meerwein, S.
Kameda, H.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 991 - 992
[46] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Orbai, Ana-Maria
Gellett, Amanda M.
Kerr, Lisa
Constantin, Arnaud
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[47] Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Cohen, Stanley B.
Chen, Yi-Hsing
Sugiyama, Naonobu
Rivas, Jose L.
Diehl, Annette
Lukic, Tatjana
Paulissen, Jerome
Fan, Haiyun
Hirose, Tomohiro
Keystone, Edward C.
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[48] Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study
D'Agostino, Maria
Schett, Georg
Lopez-Rdz, Alejandra
Senolt, Ladislav
Maldonado-Cocco, Jose
Burgos-Vargas, Ruben
Naredo, Esperanza
Carron, Philippe
Boers, Maarten
Duggan, Anne-Marie
Goyanka, Punit
Gaillez, Corine
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[49] Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Warren, Richard B.
Pavlovsky, Lev
Costanzo, Antonio
Bukhalo, Michael
Korman, Neil J.
Huang, Yu-Huei
Kokolakis, Georgios
Pinter, Andreas
Ibrahim, Nadia
Zheng, Yanbing
Drogaris, Leonidas
Stakias, Vassilis
Soliman, Ahmed M.
Rubant, Simone
Thaci, Diamant
DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3273 - 3290
[50] DESIGNING A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF GUSELKUMAB DOSING INTERVAL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION
Ogdie, A.
Merola, J. F.
Mease, P. J.
Ritchlin, C. T.
Scher, J. U.
Chan, D.
Chakravarty, S. D.
Langholff, W.
Choi, O.
Krol, Y.
Rowland, K.
Gottlieb, A. B.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1567 - 1568

← 1 2 3 4 5 →